Stopping Zepbound: No FDA Taper, What Withdrawal Trials Show

Editorial evidence status: This page was reconciled to the current 2026 FDA label and primary randomized withdrawal and maintenance trials on August 29, 2026. Medical review is pending. It does not prescribe an individual taper, maintenance dose, or restart schedule.

Separate "Can I Stop?" From "What Happens Next?"

Zepbound does not cause a recognized classic withdrawal syndrome or physical dependence. The current FDA label does not require a taper and does not publish a dose-reduction schedule for discontinuation [1]. That means a fixed 15-to-10-to-5-to-2.5 mg ladder is not label-backed.

Stopping still matters. Zepbound is indicated to reduce excess body weight and maintain weight reduction long term, and it also treats moderate to severe obstructive sleep apnea in adults with obesity [1]. Appetite, weight, blood pressure, glucose, sleep-apnea burden, and medication needs can change when treatment ends. The correct plan follows the reason for stopping and the benefits that need replacement or observation.

Stop-or-Maintain Evidence Map

The key information gain is the distinction between dose reduction as continued treatment and tapering to discontinuation. SURMOUNT-MAINTAIN tested 5 mg as a randomized maintenance strategy, not as a four-week waypoint on the way to zero. Current ADA obesity-pharmacotherapy standards similarly recommend continuing effective medication after treatment goals are reached, while balancing the maintenance dose against benefit and tolerability [5]. They do not supply a Zepbound taper-to-zero protocol.

What SURMOUNT-4 Actually Found

SURMOUNT-4 enrolled adults with obesity or overweight plus a weight-related complication and excluded diabetes. After a 36-week open-label tirzepatide lead-in, 670 participants who reached a maximum tolerated 10 or 15 mg dose were randomized [2].

From week 36 to week 88, participants switched to placebo gained a mean 14.0% of body weight, while those continuing tirzepatide lost another 5.5%. At week 88, 89.5% of continuing participants maintained at least 80% of the initial weight loss, compared with 16.6% after the placebo switch [2].

Those are group averages after a trial-defined abrupt withdrawal. They do not forecast the timing or amount of regain for one person. The trial also did not compare abrupt stopping with a gradual taper.

Louis J. Aronne, MD, and the SURMOUNT-4 investigators summarized the randomized result this way: "withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction" [2]. That conclusion belongs to the trial population and design; it is not an endorsement of indefinite treatment for every patient.

What the 2026 Maintenance Trial Adds

SURMOUNT-MAINTAIN asked a different question. After a 60-week weight-loss phase at a maximum tolerated dose of 10 or 15 mg, 378 participants were randomized to continue that dose, reduce to 5 mg, or switch to placebo for another 52 weeks [3].

The model-estimated total change from the original baseline at week 112 was minus 21.9% with continued maximum tolerated dose, minus 16.6% with 5 mg, and minus 9.9% with placebo. The study allowed rescue tirzepatide after week 84 for people who regained more than half of lost weight [3].

This trial supports a conversation about continued lower-dose maintenance for some adults. It does not authorize self-switching to 5 mg, extending intervals, splitting doses, or treating 5 mg as a proven withdrawal taper. Indication, product availability, tolerability, and the individual's prior dose still matter.

Build the Plan Around the Reason for Change

This table does not decide the outcome. It makes the decision reproducible and keeps an urgent stop, access-driven interruption, and planned long-term transition from being treated as the same generic taper.

What to Monitor Without Inventing a Calendar

The relevant endpoints are the ones Zepbound was changing. A person treated for weight-related risk may track weight trajectory, waist measure if clinically useful, blood pressure, function, appetite, and co-medication needs. A person with diabetes also needs a glucose plan. Someone treated for obstructive sleep apnea needs the sleep-care team's criteria for symptoms and positive-airway-pressure management.

A post hoc SURMOUNT-4 analysis found that larger regain categories after withdrawal were associated with greater reversal in waist circumference, systolic blood pressure, non-HDL cholesterol, HbA1c, and fasting insulin [4]. That supports outcome-linked follow-up. It does not establish mandatory blood tests at weeks 4, 8, and 12 for everyone.

Write down:

• the last dose, strength, and date;
• the reason treatment is changing;
• which benefit is most important to preserve;
• other weight, glucose, blood-pressure, or sleep treatments;
• the measurement or symptom that will trigger contact;
• who owns follow-up; and
• whether the plan is permanent discontinuation, a hold, continued lower-dose treatment, or a transition.

Appetite Return Is Not Proof of Withdrawal Injury

Tirzepatide has an approximately five-day half-life [1]. Its effects decline over time after the last dose, and appetite may increase as pharmacologic appetite regulation wanes. That is different from a dangerous withdrawal syndrome.

The current evidence does not prove that tapering lets the gut-brain axis "recalibrate," prevents an appetite overshoot, or avoids weight regain. It also does not support precise claims that hunger returns for most people within one to three weeks. Individual experience varies, and a change in appetite belongs in the follow-up record rather than a promised timeline.

A Restart Is a Separate Decision

The Zepbound label explains what to do after one missed dose: take it within four days, otherwise skip it, while keeping at least 72 hours between doses [1]. It does not publish a universal restart dose after several missed weeks or months.

Do not assume that every restart begins at 2.5 mg or that the old maintenance dose is safe after a long interruption. The Zepbound restart evidence guide separates the label rule from clinical-trial procedures and the unresolved individual decision.

If the stop followed a suspected extra dose, use the Zepbound overdose guide rather than creating a future schedule before the dose error is assessed. Older adults can use the age-65 evidence map to connect function, hydration, and co-medications to the decision without treating age itself as a contraindication.

Bottom Line

There is no evidence-based universal Zepbound taper. The strongest randomized evidence says that continued treatment preserves more weight loss than withdrawal, and newer evidence shows that continued 5 mg maintenance can preserve more than placebo after high-dose treatment. Whether to continue, reduce, hold, transition, or stop still depends on the reason for change and the outcome that needs protection.